PCAT1

Summary

PCAT1 (prostate cancer associated transcript 1, HGNC:43022) is a long non-coding RNA gene on chromosome 8q24.21.

This gene produces a long non-coding RNA that promotes cell proliferation and is upregulated in prostate, colorectal, and other cancers. This RNA negatively regulates the BRCA2 tumor suppressor protein and positively regulates Myc oncoprotein. It contains binding sites for microRNAs, and may act as a sponge for microRNAs that regulate cell growth pathways.

Source: NCBI Gene 100750225 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:43022
Approved symbol	PCAT1
Name	prostate cancer associated transcript 1
Location	8q24.21
Locus type	RNA, long non-coding
Status	Approved
Aliases	PCAT-1, PCA1, PiHL
Ensembl gene	ENSG00000253438
Ensembl biotype	lncRNA
OMIM	616043
Entrez	100750225
RNAcentral	URS00000C0582 — lncRNA, 1992 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 63 — 63 lncRNA

ENST00000517773, ENST00000517915, ENST00000519319, ENST00000519880, ENST00000520512, ENST00000521586, ENST00000524320, ENST00000561978, ENST00000642795, ENST00000643079, ENST00000643101, ENST00000643118, ENST00000643428, ENST00000643594, ENST00000643742, ENST00000644021, ENST00000644323, ENST00000644570, ENST00000644588, ENST00000644594, ENST00000644627, ENST00000644733, ENST00000644842, ENST00000644994, ENST00000645130, ENST00000645198, ENST00000645215, ENST00000645463, ENST00000645490, ENST00000646670, ENST00000646972, ENST00000647190, ENST00000689472, ENST00000690964, ENST00000740011, ENST00000740012, ENST00000740013, ENST00000740014, ENST00000740015, ENST00000740016, ENST00000740017, ENST00000740018, ENST00000740019, ENST00000740020, ENST00000740021, ENST00000740022, ENST00000740023, ENST00000740024, ENST00000740025, ENST00000740026, ENST00000740027, ENST00000740028, ENST00000740029, ENST00000740030, ENST00000740031, ENST00000740033, ENST00000740034, ENST00000740035, ENST00000740036, ENST00000740037, ENST00000740038, ENST00000843257, ENST00000843258

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000517773 — 3 exons

Exon	Start	End
ENSE00002123032	126589192	126589290
ENSE00003827864	126617389	126618500
ENSE00004075745	126557486	126557931

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 85.06.

FANTOM5 (CAGE): breadth broad, TPM avg 2.0243 / max 64.9939, expressed in 641 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
90613	1.2309	482
90612	0.2588	94
205316	0.2322	87
90629	0.1143	45
90609	0.0748	33
90611	0.0598	20
90625	0.0310	13
90610	0.0226	3

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.06	gold quality
sural nerve	UBERON:0015488	82.14	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.89	gold quality
tonsil	UBERON:0002372	78.79	gold quality
right lobe of liver	UBERON:0001114	77.58	gold quality
colonic epithelium	UBERON:0000397	77.19	gold quality
endometrium	UBERON:0001295	77.14	gold quality
bone marrow cell	CL:0002092	77.12	gold quality
liver	UBERON:0002107	76.65	gold quality
corpus callosum	UBERON:0002336	76.33	gold quality
calcaneal tendon	UBERON:0003701	76.25	gold quality
testis	UBERON:0000473	75.92	gold quality
cortex of kidney	UBERON:0001225	75.19	gold quality
left testis	UBERON:0004533	75.16	gold quality
metanephros cortex	UBERON:0010533	74.62	gold quality
kidney	UBERON:0002113	74.08	gold quality
right testis	UBERON:0004534	73.92	gold quality
adult mammalian kidney	UBERON:0000082	71.54	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	71.47	gold quality
bone marrow	UBERON:0002371	71.14	gold quality
saliva-secreting gland	UBERON:0001044	70.80	gold quality
ventricular zone	UBERON:0003053	70.61	gold quality
minor salivary gland	UBERON:0001830	70.03	gold quality
adrenal tissue	UBERON:0018303	69.76	gold quality
blood	UBERON:0000178	69.14	gold quality
granulocyte	CL:0000094	68.79	gold quality
esophagus mucosa	UBERON:0002469	68.18	gold quality
cortical plate	UBERON:0005343	68.18	gold quality
lower esophagus mucosa	UBERON:0035834	67.80	gold quality
gall bladder	UBERON:0002110	67.74	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.73

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• Findings suggest that PCAT-1 is a transcriptional repressor implicated in a subset of prostate cancer patients. (PMID:21804560)
• Explored the correlation between PCAT-1 expression and the progression of CRC. Found CRC patients with PCAT-1 higher expression have shown significantly poorer overall survival than those with lower PCAT-1 expression. (PMID:23640607)
• PCAT-1 expression produces a functional deficiency in homologous recombination through its repression of the BRCA2 tumor suppressor. (PMID:24473064)
• Data indicate that proto-oncogene protein cMyc is required for PCAT-1-mediated cell proliferation. (PMID:25425964)
• High expression of PCAT-1 might reflect poor prognosis of ESCC and indicate a potential diagnostic target in ESCC patients. Adjuvant therapy targeting PCAT-1 molecule might be effective in treatment of ESCC. (PMID:25731728)
• PCAT-1 plays oncogenic roles and can be used as a therapeutic target for treating human bladder cancer. (PMID:25934337)
• Increased expression of PCAT-1 was associated with advanced clinical parameters and poor overall survival of HCC patients. (PMID:26097602)
• Modulation of lncRNAs by risk-associted SNPs contributes to men’s genetic susceptibility to prostate cancer. LncRNAs are an attractive target for novel therapeutics to mitigate cancer risk. (PMID:27578041)
• The expression levels of serum PCAT-1 in MM patients were significantly higher than that in healthy controls, suggesting that it may be useful in the auxiliary diagnosis of MM. (PMID:28085010)
• PCAT-1 regulates gastric cancer cell proliferation and migration through CDKN1A regulation. The over-expression of PCAT-1 is associated with poor prognosis. (PMID:28571676)
• Genetic variants in lncRNA PCAT1 are associated with bladder cancer susceptibility and the SNP rs710886 may act as a potential biomarker for bladder cancer risk. (PMID:28627442)
• finding suggested that PCAT-1 may have potential roles as a biomarker and/or a therapeutic target in gastric cancer. (PMID:28742205)
• These findings revealed an important role of PCAT1 in Extrahepatic cholangiocarcinoma. (PMID:28753454)
• study revealed a tumorigenic effect of long nnon-coding RNA PCAT-1 in Colorectal Ccancer cells, and this effect is partly dependent on the inhibition of c-myc. (PMID:28855110)
• the findings outlined in the current study suggest that PCAT-1 regulates the invasiveness and drug resistance in CRC cells and that PCAT-1 may promote CRC cell invasion by modulating the expression of c-Myc. (PMID:28884413)
• TP53-miR-215-PCAT-1-CRKL axis might represent an important regulatory pathway in hepatocellular carcinoma. (PMID:28887306)
• PCAT-1 accelerated prostate cancer cell proliferation, migration, invasion and suppressed apoptosis by up-regulating FSCN1 mediated via miR-145-5p. (PMID:28922730)
• PCAT-1 repressed inhibitory effect of miR-129-5p and reverse high mobility group box 1 (HMGB1) expression, a target gene of miR-129-5p. (PMID:28931210)
• The LncRNA PART1 promoted cell proliferation ability and apoptosis via the inhibition of TLR pathways in prostate cancer. LncRNA PART1 could hence be considered as a new target in the treatment of prostate cancer. (PMID:29261512)
• The PCAT-1 expression is closely correlated with depth of infiltration, lymph node metastasis, distant metastasis and TNM stage, and that increased PCAT-1 expression may be a potential prognostic biomarker in human cancers. However, more large-scale studies are warranted. (PMID:29378170)
• lncRNA PCAT-1 expression can inhibit the proliferation, metastasis and invasion abilities of cervical cancer cells. (PMID:29687842)
• MiR-145-5p could reverse the effects of PCAT1 and TLR4 in hADSCs osteogenic differentiation. LncRNA-PCAT1 negatively regulated miR-145-5p, which promoted TLR4 expression to promote osteogenic differentiation by activating the TLR signalling pathway. (PMID:30338912)
• High expression of PCAT-1 was related to deeper tumor invasion, lymph node metastasis, advanced clinical stage and poor prognosis and could be a promising biomarker of gastrointestinal cancers. (PMID:30508953)
• Long non-coding RNA PCAT1 (PCAT1) had higher expression in glioma stem cells (GSCs). (PMID:30564876)
• LncRNA PCAT1 activates AKT and NF-kappaB signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKalpha complex. (PMID:30773595)
• Our results for the first time demonstrated an important role of lncRNA PCAT-1 in HNSCC proliferation and apoptosis in in-vitro and in-vivo systems. (PMID:30987615)
• PCAT-1 is overexpressed in oral squamous cell carcinoma and is associated with higher morbidity (PMID:31081003)
• series of functional assays showed that the knockdown of PCAT1 by small interfering RNA (siRNA) targeting PCAT1 (siPCAT1) suppressed cell proliferation, migration and invasion, but promoted apoptosis (PMID:31136293)
• lncRNA-PCAT1 rs2632159 polymorphism could be a biomarker for colorectal cancer susceptibility. (PMID:31253700)
• PCAT1 promotes oesophageal squamous cell carcinoma (ESCC) cell proliferation by sponging miR-326 and may serve as a non-invasive biomarker for ESCC. (PMID:31273188)
• PCAT-1 confers cisplatin resistance in gastric cancer cells through miR-128/ZEB1 axis. (PMID:31352238)
• Polymorphisms in lncRNA-PCAT1 might be associated with lung cancer susceptibility in a northeastern Chinese population. (PMID:31464517)
• PCAT-1 contributes to cisplatin resistance in gastric cancer through epigenetically silencing PTEN via recruiting EZH2. (PMID:31478258)
• SNP rs710886 A>G in long noncoding RNA PCAT1 is associated with the risk of endometriosis by modulating expression of multiple stemness-related genes via microRNA-145 signaling pathway. (PMID:31595574)
• PCAT1 promotes the proliferative and migratory potentials of ovarian cancer via targeting NEK2. (PMID:31646554)
• LncRNA PCAT-1 regulated cell proliferation, invasion, migration and apoptosis in colorectal cancer through targeting miR-149-5p. (PMID:31646561)
• High PCAT1 expression is associated with laryngeal cancer. (PMID:31983116)
• PCAT-1 promotes cell growth by sponging miR-129 via MAP3K7/NF-kappaB pathway in multiple myeloma. (PMID:32048803)
• PCAT1/miR-129/ABCB1 axis confers chemoresistance in non-small cell lung cancer. (PMID:32114419)
• PCAT1: An oncogenic lncRNA in diverse cancers and a putative therapeutic target. (PMID:32220602)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.